Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its secondary endpoint (p = 0.368).

The European Medicines Agency (EMEA) has recommended that the appetite suppressant sibutramine, also known as Reductil, should no longer be prescribed by doctors and that pharmacists should no longer dispense the drug.

New research has found giving up caffeine does not relieve tinnitus and acute caffeine withdrawal might add to the problem. This is the first study of its kind to look at the effect of caffeine consumption on tinnitus.

New research suggests that tiotropium, a long-acting anticholinergic used in patients with COPD, may be associated with a reduction in all-cause mortality, cardiovascular mortality, and cardiovascular events. Researchers from Caritas-St. Elizabeth Medical Center in Boston, MA, reviewed the outcomes of 30 completed clinical trials in the tiotropium project database. Within the trials, 10,846 patients were [...]

A new study which has been conducted at the University of Bologna shows that brief psychological interventions in school may increase well-being among adolescents and these results persist after 6 months